Key facts
- Stipple Bio’s last known valuation is $2.2B (Apr 2026).
- It has raised $121.5M across 2 recorded rounds; the latest was Later Stage VC ($65.1M) in Mar 2026.
- Notable investors include Andreessen Horowitz, RA Capital Management, GV, Emerson Collective, Magnetic Ventures — 10 tracked in total.
- Stipple Bio has filed 1 Form D with the SEC, most recently Dec 2024 ($9.5M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Stipple Bio
Funding rounds
2 roundsAbout Stipple Bio
Operator of a biotechnology company intended to unlock cellular profiling and target discovery. The company offers epitope-level resolution technology for single-cell profiling and allows the identification of novel therapeutic targets and the development of precision therapies, enabling users with therapies for a wide range of solid and hematologic malignancies.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2022
- Employees
- 7
- Website
- stipple.bio/
- Ownership
- Privately Held (backing)
Stipple Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Stipple Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Stipple Bio in its N-PORT filings yet. We sweep new filings monthly.